Stock listing
NYSE American:AEON AEON Biopharma, Inc. Stock
Home listing (NYSE American) of AEON Biopharma, Inc.
Follow AEON Biopharma, Inc. into a list and get an email when it puts out news.
Share price · AMEX:AEON
$0.123 USD -0.001 (-1.0%)
Close on Nov 20, 2026
- Day range
- $0.122 – $0.135 USDNov 20, 2026
- Volume
- 1.17M sharesNov 20, 2026
- Market cap
- $7.27M USDAt the close on Nov 20, 2026 · price × 59.08M shares outstanding
- 52-week range
- $0.107 – $1.450 USDLowest and highest trades, Nov 21, 2025 – Nov 20, 2026
- Traded on an average day
- $2.05M USDMedian day 956,900 shares · last 3 months, Aug 20, 2026 – Nov 20, 2026

Prices by listing
| Listing | Last | Change | Volume | Open | High | Low | Previous close | Price from |
|---|---|---|---|---|---|---|---|---|
| NYSE American:AEON · Home | $0.123 USD | -0.001 (-1.0%) | 1,166,109 | $0.133 | $0.135 | $0.122 | $0.124 | Close on Nov 20, 2026 |
Daily closes
Last 3 months, Aug 20, 2026 – Nov 20, 2026 · AMEX:AEON · USD, adjusted for splits
| Day | Close | Change | % | Open | High | Low | Volume |
|---|---|---|---|---|---|---|---|
| $0.123 | -0.001 | -1.0% | $0.133 | $0.135 | $0.122 | 1,166,109 | |
| $0.124 | +0.011 | +9.6% | $0.115 | $0.133 | $0.115 | 1,840,987 | |
| $0.113 | -0.027 | -19.4% | $0.156 | $0.156 | $0.107 | 7,407,638 | |
| $0.141 | -0.012 | -8.0% | $0.152 | $0.163 | $0.141 | 543,569 | |
| $0.153 | -0.006 | -3.6% | $0.161 | $0.170 | $0.153 | 785,920 | |
| $0.159 | -0.013 | -7.4% | $0.170 | $0.182 | $0.159 | 247,784 | |
| $0.171 | -0.008 | -4.4% | $0.180 | $0.182 | $0.170 | 201,341 | |
| $0.179 | -0.003 | -1.4% | $0.181 | $0.184 | $0.171 | 229,135 | |
| $0.182 | +0.006 | +3.4% | $0.180 | $0.185 | $0.166 | 518,742 | |
| $0.176 | +0.018 | +11.3% | $0.160 | $0.180 | $0.151 | 900,142 | |
| $0.158 | -0.051 | -24.4% | $0.219 | $0.219 | $0.127 | 2,678,300 | |
| $0.209 | -0.003 | -1.4% | $0.216 | $0.227 | $0.209 | 6,550,800 | |
| $0.212 | -0.061 | -22.3% | $0.275 | $0.275 | $0.211 | 1,081,300 | |
| $0.273 | -0.001 | -0.4% | $0.277 | $0.299 | $0.270 | 323,900 | |
| $0.274 | -0.020 | -6.8% | $0.284 | $0.290 | $0.270 | 774,400 | |
| $0.294 | +0.030 | +11.4% | $0.264 | $0.310 | $0.264 | 1,339,500 | |
| $0.264 | +0.016 | +6.5% | $0.249 | $0.269 | $0.244 | 728,300 | |
| $0.248 | +0.008 | +3.3% | $0.240 | $0.255 | $0.240 | 139,800 | |
| $0.240 | 0.000 | 0.0% | $0.235 | $0.250 | $0.235 | 108,000 | |
| $0.240 | +0.006 | +2.6% | $0.235 | $0.243 | $0.231 | 198,900 | |
| $0.234 | -0.006 | -2.5% | $0.237 | $0.240 | $0.233 | 112,800 | |
| $0.240 | +0.008 | +3.4% | $0.236 | $0.250 | $0.236 | 145,700 | |
| $0.232 | +0.001 | +0.4% | $0.238 | $0.241 | $0.220 | 307,900 | |
| $0.231 | -0.001 | -0.4% | $0.241 | $0.249 | $0.231 | 459,000 | |
| $0.232 | -0.011 | -4.5% | $0.236 | $0.248 | $0.231 | 240,500 | |
| $0.243 | +0.014 | +6.1% | $0.232 | $0.252 | $0.231 | 391,400 | |
| $0.229 | -0.001 | -0.4% | $0.230 | $0.241 | $0.225 | 1,127,100 | |
| $0.230 | -0.016 | -6.5% | $0.242 | $0.250 | $0.225 | 1,289,100 | |
| $0.246 | -0.030 | -10.9% | $0.274 | $0.284 | $0.243 | 1,077,700 | |
| $0.276 | -0.034 | -11.0% | $0.310 | $0.319 | $0.276 | 1,618,500 | |
| $0.310 | -0.001 | -0.3% | $0.312 | $0.324 | $0.292 | 1,133,900 | |
| $0.311 | +0.021 | +7.2% | $0.293 | $0.333 | $0.285 | 2,916,200 | |
| $0.290 | +0.020 | +7.4% | $0.264 | $0.295 | $0.264 | 2,259,200 | |
| $0.270 | -0.009 | -3.2% | $0.280 | $0.280 | $0.249 | 1,740,900 | |
| $0.279 | -0.011 | -3.8% | $0.300 | $0.300 | $0.260 | 3,233,700 | |
| $0.290 | -0.010 | -3.3% | $0.300 | $0.334 | $0.277 | 6,638,000 | |
| $0.300 | +0.041 | +15.8% | $0.321 | $0.419 | $0.240 | 116,174,700 | |
| $0.259 | -0.003 | -1.1% | $0.263 | $0.265 | $0.255 | 194,900 | |
| $0.262 | -0.002 | -0.8% | $0.261 | $0.270 | $0.260 | 310,700 | |
| $0.264 | +0.004 | +1.5% | $0.262 | $0.271 | $0.258 | 565,200 | |
| $0.260 | -0.004 | -1.5% | $0.265 | $0.269 | $0.255 | 561,700 | |
| $0.264 | +0.002 | +0.8% | $0.268 | $0.285 | $0.260 | 1,282,500 | |
| $0.262 | +0.008 | +3.1% | $0.258 | $0.265 | $0.252 | 398,500 | |
| $0.254 | +0.011 | +4.5% | $0.255 | $0.260 | $0.243 | 661,800 | |
| $0.243 | -0.003 | -1.2% | $0.254 | $0.267 | $0.240 | 2,090,600 | |
| $0.246 | -0.011 | -4.3% | $0.244 | $0.250 | $0.232 | 1,467,500 | |
| $0.257 | -0.009 | -3.4% | $0.267 | $0.277 | $0.251 | 1,512,600 | |
| $0.266 | -0.020 | -7.0% | $0.278 | $0.278 | $0.251 | 2,083,400 | |
| $0.286 | -0.041 | -12.5% | $0.326 | $0.345 | $0.252 | 6,189,500 | |
| $0.327 | +0.037 | +12.8% | $0.298 | $0.380 | $0.290 | 31,010,500 | |
| $0.290 | +0.059 | +25.5% | $0.296 | $0.354 | $0.280 | 203,622,400 | |
| $0.231 | -0.004 | -1.7% | $0.248 | $0.248 | $0.231 | 470,300 | |
| $0.235 | -0.006 | -2.5% | $0.245 | $0.245 | $0.230 | 156,000 | |
| $0.241 | -0.014 | -5.5% | $0.258 | $0.276 | $0.240 | 758,600 | |
| $0.255 | -0.016 | -5.9% | $0.279 | $0.279 | $0.250 | 374,100 | |
| $0.271 | -0.006 | -2.2% | $0.272 | $0.280 | $0.268 | 194,500 | |
| $0.277 | -0.019 | -6.4% | $0.283 | $0.287 | $0.263 | 363,800 | |
| $0.296 | -0.018 | -5.7% | $0.308 | $0.310 | $0.286 | 506,200 | |
| $0.314 | +0.020 | +6.8% | $0.299 | $0.316 | $0.280 | 1,107,500 | |
| $0.294 | +0.042 | +16.7% | $0.254 | $0.314 | $0.252 | 4,701,200 | |
| $0.252 | +0.040 | +18.9% | $0.211 | $0.253 | $0.211 | 4,048,500 | |
| $0.212 | +0.015 | +7.6% | $0.203 | $0.330 | $0.190 | 40,763,600 | |
| $0.197 | +0.005 | +2.6% | $0.201 | $0.202 | $0.190 | 956,900 | |
| $0.192 | -0.001 | -0.5% | $0.192 | $0.207 | $0.180 | 1,722,300 | |
| $0.193 | -0.005 | -2.5% | $0.205 | $0.208 | $0.177 | 2,239,000 |
Splits
1 split · AMEX:AEON · every price before a split is adjusted for it
| Day | Ratio | What |
|---|---|---|
| 1-for-72 | Consolidation |
- Ticker
- NYSE American:AEON
- Asset type
- Stock
- Sector
- Health care
- Industry
- Biotechnology
- Exchange
- NYSE American
- Currency
- USD
What changed lately
Latest news release · Nov 9, 2026
AEON Biopharma Submits IND for Comparative Pharmacodynamic Study of ABP-450
Latest deck · October 2026
Investor Presentation (October 2026)
Investor deck · 33 slides
Latest news
AEON Biopharma Submits IND for Comparative Pharmacodynamic Study of ABP-450
Nov 9, 2026
Closed $0.182 (+3.4%) on Nov 9, 2026
AEON Biopharma Reports Second Quarter 2026 Financial Results and Provides Corporate Update
Aug 12, 2026
Closed $0.271 (-1.5%) on Aug 13, 2026
AEON Biopharma Regains Compliance with NYSE American Continued Listing Standards
Aug 3, 2026
Closed $0.296 (+0.3%) on Aug 4, 2026
AEON Biopharma Announces Pricing of Upsized $13.75 Million Public Offering with Accompanying Milestone Warrants Providing Potential for Additional Future Funding
Jul 14, 2026
Closed $0.357 (+10.9%) on Jul 14, 2026
AEON Biopharma to Present Data Demonstrating Structural and Functional Comparability of ABP-450 to BOTOX® at the 68th Annual Scientific Meeting of the American Headache Society
Jun 4, 2026
Closed $0.737 (+0.7%) on Jun 4, 2026
AEON Biopharma Reports First Quarter 2026 Financial Results and Provides Corporate Update
May 14, 2026
Closed $0.722 (-9.9%) on May 15, 2026
AEON Biopharma Sets Annual Shareholder Meeting
Apr 24, 2026
Closed $1.04 (-1.0%) on Apr 27, 2026
AEON Biopharma Reports Inducement Grants Under NYSE American LLC Company Guide Section 711
Apr 3, 2026
Closed $0.91 (+2.4%) on Apr 6, 2026
AEON Biopharma Receives Additional Notice Related to NYSE American Continued Listing Standards
Apr 3, 2026
Closed $0.91 (+2.4%) on Apr 6, 2026
AEON Biopharma, Inc. on 6ix
- Sector
- Health care
- Industry
- Biotechnology
- News releases
- 15 in the last 12 months · 23 in all · newest Nov 9, 2026 · oldest 2024
- Decks
- 16 decks · latest October 2026
Where AEON Biopharma, Inc. is listed
| Listing | Exchange | Country | Currency |
|---|---|---|---|
| NYSE American:AEON · Home listing · This page | NYSE American | United States | USD |
| BOATS:AEON | BOATS | United States | USD |
Cash and shares
May 14, 2026 · AEON Biopharma — Investor Presentation (May 2026)
- Cash
- $1.5 million
Valuation
Price/book 3.0× against a median of 1.2×: 7th lowest of 10 Biotechnology companies shown. Statements: 4 quarters to Sep 30, 2026 · price Nov 20, 2026
- Enterprise value
- −$4.15M USD
- P/E
- Loss
- EV/sales
- No revenue
- EV/EBITDA
- No depreciation figure on 6ix yet
- Price/book
- 3.0×
- Gross margin
- No revenue
- Operating margin
- No revenue
- Net margin
- No revenue
- Debt to equity
- 0.0×
- Beta vs S&P 500
- 1.04
Biotechnology: the 10 companies nearest in size, of 890 on 6ix with figures. Size in US dollars.
| Company | Mkt cap | EV | P/E | EV/Sales | EV/EBITDA | P/B | Net mgn | Debt/Eq | Beta |
|---|---|---|---|---|---|---|---|---|---|
| AEON Biopharma, Inc. · AMEX:AEON | US$7.27M | −US$4.15M | n/a | n/a | n/a | 3.0× | n/a | 0.0× | 1.04 |
| Annexin Pharmaceuticals AB · OMXSTO:ANNX | US$7.59M | US$6.18M | n/a | n/a | n/a | 6.3× | n/a | 0.0× | n/a |
| Solvonis Therapeutics PLC · LSE:SVNS | US$7.57M | US$6.80M | n/a | n/a | n/a | 1.2× | n/a | 0.0× | n/a |
| Vistagen Therapeutics, Inc. · NASDAQ:VTGN | US$7.56M | −US$11.87M | n/a | −5.0× | n/a | 0.5× | n/a | 0.0× | 1.47 |
| Noxopharm Ltd. · ASX:NOX | US$7.52M | US$10.36M | n/a | 11.0× | n/a | n/a | −312.2% | n/a | n/a |
| Ascelia Pharma AB · OMXSTO:ACE | US$7.30M | US$3.63M | n/a | n/a | n/a | 0.8× | n/a | 0.0× | n/a |
| Pila Pharma AB · OMXSTO:PILA | US$7.01M | US$6.70M | n/a | n/a | n/a | 4.5× | n/a | 0.0× | n/a |
| Cadrenal Therapeutics, Inc. · NASDAQ:CVKD | US$7.01M | US$3.95M | n/a | n/a | n/a | 2.4× | n/a | 0.0× | 1.60 |
| Ensysce Biosciences, Inc. · NASDAQ:ENSC | US$7.00M | −US$22.51M | n/a | −3.6× | n/a | 0.3× | n/a | 0.0× | 1.28 |
| Arctic Bioscience AS · OSL:ABS | US$7.00M | US$11.38M | n/a | 2.8× | n/a | 0.4× | −102.3% | 0.3× | n/a |
| Alaunos Therapeutics, Inc. · NASDAQ:TCRT | US$6.99M | US$6.37M | n/a | 2,124× | n/a | 7.2× | n/a | 0.0× | 0.90 |
| Median of the others | US$7.16M | US$6.27M | 2.8× | 1.2× | −207.2% | 0.0× | 1.38 |
Forecasts
1 strong buy · Analysts' consensus from EODHD, read Nov 19, 2026. Not 6ix's view and not investment advice.
- Price target
- 1.82 USD · Analysts' mean
- EPS, year to Dec 2026
- -0.45 · 3 analysts
Team and board
Officers
| Officer | Role |
|---|---|
| Rob Bancroft | President & CEO |
| John Bencich | Chief Financial Officer - |
| Alex Wilson | Chief Legal & Strategy Officer, Secretary |
| Chad Oh | Chief Medical Officer |
| Jennifer Sy | Chief Accounting Officer |
| Paul Lee | Chief Regulatory Officer |
Board
| Director | Role |
|---|---|
| Jost Fischer | Chairman and Board Member |
| Eric Carter | Board Member |
| Marc Forth | Board Member |
| Rob Bancroft | President & CEO |
| Robert Palmisano | Board Member |
| Shawn Park | Board Member |
| Shelley Thunen | Board Member |
Events
| Quarter | Results | Share move |
|---|---|---|
| Q3 2026 | Nov 16, 2026 · After close | −19.4% |
| Q2 2026 | Aug 12, 2026 · After close | −1.4% |
| Q1 2026 | May 14, 2026 · After close | −9.9% |
| Q3 2025 | Nov 14, 2025 · Before open | −3.7% |
| Q2 2025 | Aug 12, 2025 · After close | +16.1% |
| Q1 2025 | May 14, 2025 | −1.8% |
| Q4 2024 | Mar 24, 2025 | +0.1% |
| Q3 2024 | Nov 13, 2024 · After close | −11.3% |
| Q2 2024 | Aug 12, 2024 · After close | −1.0% |
| Q1 2024 | May 14, 2024 · After close | −3.1% |
All 15 quarters
| Quarter | Results | Share move |
|---|---|---|
| Q4 2023 | Mar 29, 2024 · After close | −36.0% |
| Q3 2023 | Nov 13, 2023 · Before open | −1.2% |
| Q2 2023 | Aug 30, 2023 | +32.8% |
| Q1 2023 | May 31, 2023 | −0.7% |
| Q3 2021 | Oct 4, 2021 |
Decks
| Deck | Kind | Slides | Date |
|---|---|---|---|
| Investor Presentation (October 2026) | Investor deck | 33 slides | October 2026 |
| Investor Presentation (August 2026) | Investor deck | 31 slides | August 2026 |
| Investor Presentation (May 2026) | Investor deck | 31 slides | May 14, 2026 |
| Investor Presentation (January 2026) | Investor deck | 30 slides | Jan 12, 2026 |
| Investor Presentation (December 2025) | Investor deck | 26 slides | Dec 4, 2025 |
| Investor Presentation (September 2025) | Investor deck | 24 slides | Sep 8, 2025 |
| Aegis Capital Healthcare Conference May 2025 | Conference | 14 slides | May 20, 2025 |
| Investor Presentation (March 2025) | Investor deck | 17 slides | Mar 10, 2025 |
| Investor Presentation (October 2024) | Investor deck | 25 slides | Oct 7, 2024 |
| Investor Presentation (August 2024) | Investor deck | 26 slides | Aug 6, 2024 |
All 16 decks
| Deck | Kind | Slides | Date |
|---|---|---|---|
| Investor Presentation (October 2023) | Investor deck | 34 slides | Oct 19, 2023 |
| Technical Presentation (October 2023) | Technical | 21 slides | Oct 19, 2023 |
| Priveterra Acquisition — SPAC Merger (July 2023) | SPAC merger | 35 slides | Jul 24, 2023 |
| Priveterra Acquisition — SPAC Merger (May 2023) | SPAC merger | 48 slides | May 24, 2023 |
| Priveterra Acquisition — SPAC Merger (February 2023) | SPAC merger | 41 slides | Feb 24, 2023 |
| SPAC Merger (December 2022) | SPAC merger | 37 slides | December 2022 |
Financings
| Raise | Date |
|---|---|
| Public offering of underwritten public offering with milestone warrants Closed: US$15.3M raised · US$0.3221 a share · one two-year milestone warrant (exercise price $0.3221) and one five-year milestone… · Lake Street Capital Markets, LLC +1 Dealers: Lake Street Capital Markets, LLC (lead), Laidlaw & Company (UK) Ltd. Use of proceeds: Cash runway into the first quarter of 2027, supporting advancement of the ABP-450 development program | Aug 12, 2026 |
| Private placement of pIPE financing Tranche closed: US$1.79M raised Use of proceeds: Uninterrupted execution of the analytical program and acceleration of ABP-450 biosimilar development | Jan 21, 2026 |
Open Financings · Read by 6ix AI from the company's releases
IPO
Went public as Priveterra Acquisition Corp., a blank check company (SPAC). Priced at US$10.00 a unit on Feb 8, 2021.
- Price
- US$10.00 a unit
- Units offered
- 24,000,000 units
- Offering size
- US$240 million
- Underwriters' option
- Up to 3,600,000 more units
- Listing
- PMGMU on the Nasdaq Capital Market
- Underwriters
- Wells Fargo Securities, Guggenheim Securities, Odeon Capital Group, LLC · In the order on the cover
- Units delivered
- On or about Feb 11, 2021
Steps
| Step | When |
|---|---|
| Draft sent to the SEC in confidence | Dec 23, 2020 |
| Filed publicly | Jan 21, 2021 |
| Amended once | Jan 29, 2021 |
| Shares registered with an exchange | Feb 8, 2021 |
| Declared effective by the SEC | Feb 8, 2021 |
| Final prospectus, with the price | Feb 11, 2021 |
Filings
| Filing | Filed |
|---|---|
| 424B4 · Prospectus | Feb 11, 2021 |
| S-1MEF · Registration of more shares for the same offering | Feb 9, 2021 |
| EFFECT · Notice that a registration is effective | Feb 8, 2021 |
| CERT · Exchange's certificate of listing | Feb 8, 2021 |
| 8-A12B · Registration of shares for listing on an exchange | Feb 8, 2021 |
| S-1/A · Registration statement, amended | Jan 29, 2021 |
| S-1 · Registration statement | Jan 21, 2021 |
| DRS · Draft registration statement | Dec 23, 2020 |
Open IPO · From the cover of the final prospectus (424B4) filed Feb 11, 2021
Financials
Annual, in USD
Income statement
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 2.52M | 3.36M | |
| Cost of revenue | 78.0K | 0 | 1.00K | ||||
| Gross profit | -78.0K | 2.52M | 3.36M | ||||
| Research and development | 4.09M | 14.2M | 33.0M | 34.8M | 25.7M | 7.32M | 4.81M |
| Selling, general and administrative | 12.2M | 13.6M | 13.7M | 11.2M | 11.6M | 46.0M | |
| Operating income | -12.8M | 73.0M | -348.1M | -48.4M | -1.94M | -16.4M | -54.0M |
| Depreciation and amortization | 78.0K | 97.0K | 99.0K | 68.0K | 3.00K | 875.0K | 1.26M |
| EBITDA | -12.7M | 73.1M | -348.0M | -48.4M | -1.93M | -15.5M | -52.7M |
| Interest expense | 15.0K | 7.47M | |||||
| Income before tax | -39.2M | 42.0M | -384.6M | -52.6M | 8.20M | -32.9M | 145.7M |
| Income tax | 0 | 0 | 0 | 29.0M | 15.0K | 14.6M | |
| Net income | -39.2M | 42.0M | -384.6M | -52.6M | 8.20M | -32.9M | 172.9M |
| Earnings per share, basic | -3.95 | 77.74 | -744.83 | -0.38 | 18.86 | -68.69 | 1,873.44 |
| Earnings per share, diluted | -3.95 | 72.93 | -0.38 |
Balance sheet
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|
| Cash and equivalents | 3.01M | 13.0K | 5.16M | 9.75M | 497.4K | 20.2M | 6.32M |
| Short-term investments | 0 | 105.4M | |||||
| Receivables | 0 | 267.0K | |||||
| Current assets | 3.40M | 1.59M | 6.22M | 9.84M | 835.2K | 20.4M | 112.1M |
| Property, plant and equipment | 162.0K | 235.0K | 431.0K | 922.0K | |||
| Total assets | 5.56M | 3.14M | 6.84M | 10.8M | 276.9M | 21.2M | 114.4M |
| Accounts payable | 942.0K | 5.91M | 3.39M | 7.80M | 1.19M | 2.03M | 1.02M |
| Current liabilities | 6.90M | 14.1M | 13.0M | 82.6M | 834.6K | 4.20M | 17.5M |
| Long-term debt | 34.6M | 11.7M | 60.4M | 70.8M | 72.2M | 15.2M | |
| Total debt | 35.7M | 13.0M | 278.0K | 131.5M | 86.9M | 72.2M | 30.0M |
| Total liabilities | 60.6M | 31.7M | 159.9M | 143.2M | 17.9M | 224.4M | 180.2M |
| Shareholders' equity | -55.0M | -28.6M | -153.0M | -287.5M | -16.9M | -208.3M | -67.2M |
| Shares outstanding | 12.1M | 555.5K | 516.4K | 138.8M | 434.8K | 479.2K | 92.3K |
Cash flow
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|
| Cash from operations | -17.3M | -20.3M | -47.8M | -35.6M | -1.49M | -9.46M | -44.7M |
| Capital spending | -4.00K | 0 | 0 | -306.0K | -170.0K | -170.0K | -1.69M |
| Free cash flow | -17.3M | -20.3M | -47.8M | -35.9M | -28.6M | -9.46M | -46.4M |
| Cash from investing | -4.00K | -306.0K | -276.0M | -1.26M | -117.3M | ||
| Cash from financing | 20.3M | 15.1M | 14.0M | 40.5M | 278.0M | 24.6M | 73.2M |
| Dividends paid | -83.9M | ||||||
| Share buybacks | 0 | -64.0K | |||||
| Change in cash | 2.99M | -5.14M | -4.59M | 4.62M | 497.4K | 13.8M | -88.8M |
Filings
| Filing | Date | Type | Filed with |
|---|---|---|---|
| 4 · Change in ownership | Nov 20, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Nov 20, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Nov 20, 2026 | Insider trade | SEC |
| SCHEDULE 13G · Big-stake notice | Nov 16, 2026 | Big-stake notice | SEC |
| 10-Q · Quarterly report | Nov 16, 2026 | Quarterly report | SEC |
| 8-K · Current report | Nov 16, 2026 | Results | SEC |
| SCHEDULE 13G · Big-stake notice | Nov 13, 2026 | Big-stake notice | SEC |
| SCHEDULE 13D/A · Big-stake notice, amended | Nov 10, 2026 | Big-stake notice | SEC |
| 4 · Change in ownership | Nov 10, 2026 | Insider trade | SEC |
| 424B3 · Prospectus | Nov 3, 2026 | Offer document | SEC |
Show 200 filings
| Filing | Date | Type | Filed with |
|---|---|---|---|
| 8-K · Current report | Nov 3, 2026 | Material contract | SEC |
| DEF 14A · Proxy statement | Oct 26, 2026 | Meeting notice | SEC |
| 8-K · Current report | Oct 23, 2026 | Current report | SEC |
| PRE 14A · Preliminary proxy statement | Oct 13, 2026 | Meeting notice | SEC |
| 8-K · Current report | Sep 30, 2026 | Current report | SEC |
| SCHEDULE 13G · Big-stake notice | Aug 21, 2026 | Big-stake notice | SEC |
| 4 · Change in ownership | Aug 21, 2026 | Insider trade | SEC |
| 3 · Initial statement of ownership | Aug 21, 2026 | Insider trade | SEC |
| 10-Q · Quarterly report | Aug 12, 2026 | Quarterly report | SEC |
| 8-K · Current report | Aug 12, 2026 | Results | SEC |
| 8-K · Current report | Aug 3, 2026 | Current report | SEC |
| 8-K · Current report | Jul 23, 2026 | Current report | SEC |
| SCHEDULE 13G · Big-stake notice | Jul 21, 2026 | Big-stake notice | SEC |
| 8-K · Current report | Jul 15, 2026 | Material contract | SEC |
| 424B4 · Prospectus | Jul 15, 2026 | Offer document | SEC |
| EFFECT · Notice that a registration is effective | Jul 14, 2026 | Other filings | SEC |
| S-1MEF · Registration of more shares for the same offering | Jul 13, 2026 | Offer document | SEC |
| S-1/A · Registration statement, amended | Jul 9, 2026 | Offer document | SEC |
| S-1 · Registration statement | Jul 8, 2026 | Offer document | SEC |
| 4 · Change in ownership | Jun 22, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 22, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 22, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 22, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 22, 2026 | Insider trade | SEC |
| 8-K · Current report | Jun 17, 2026 | Meeting outcome | SEC |
| DRS · Draft registration statement | May 29, 2026 | Offer document | SEC |
| 8-K · Current report | May 14, 2026 | Current report | SEC |
| 10-Q · Quarterly report | May 14, 2026 | Quarterly report | SEC |
| 8-K · Current report | May 14, 2026 | Results | SEC |
| ARS · Annual report to shareholders | Apr 29, 2026 | Annual report | SEC |
| DEFA14A · Additional proxy material | Apr 29, 2026 | Meeting notice | SEC |
| DEF 14A · Proxy statement | Apr 29, 2026 | Meeting notice | SEC |
| 4 · Change in ownership | Apr 3, 2026 | Insider trade | SEC |
| 3 · Initial statement of ownership | Apr 3, 2026 | Insider trade | SEC |
| 8-K · Current report | Apr 3, 2026 | Current report | SEC |
| S-8 · Registration statement for employee plans | Mar 30, 2026 | Offer document | SEC |
| 10-K · Annual report | Mar 30, 2026 | Annual report | SEC |
| 8-K · Current report | Mar 30, 2026 | Results | SEC |
| 4 · Change in ownership | Mar 11, 2026 | Insider trade | SEC |
| 8-K · Current report | Mar 9, 2026 | Management or board change | SEC |
| 4 · Change in ownership | Mar 5, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Mar 5, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Feb 19, 2026 | Insider trade | SEC |
| 424B3 · Prospectus | Feb 18, 2026 | Offer document | SEC |
| EFFECT · Notice that a registration is effective | Feb 18, 2026 | Other filings | SEC |
| CORRESP · Letter to the SEC | Feb 12, 2026 | Other filings | SEC |
| UPLOAD · Letter from the SEC | Feb 12, 2026 | Other filings | SEC |
| S-3 · Registration statement | Feb 9, 2026 | Offer document | SEC |
| 3 · Initial statement of ownership | Jan 29, 2026 | Insider trade | SEC |
| SCHEDULE 13D · Big-stake notice | Jan 29, 2026 | Big-stake notice | SEC |
| SCHEDULE 13D/A · Big-stake notice, amended | Jan 29, 2026 | Big-stake notice | SEC |
| 8-K · Current report | Jan 21, 2026 | Management or board change | SEC |
| 8-K · Current report | Jan 12, 2026 | Current report | SEC |
| DEF 14A · Proxy statement | Dec 29, 2025 | Meeting notice | SEC |
| PRE 14A · Preliminary proxy statement | Dec 19, 2025 | Meeting notice | SEC |
| 8-K · Current report | Dec 15, 2025 | Material contract | SEC |
| 8-K · Current report | Dec 4, 2025 | Current report | SEC |
| DEFA14A · Additional proxy material | Nov 14, 2025 | Meeting notice | SEC |
| 10-Q · Quarterly report | Nov 14, 2025 | Quarterly report | SEC |
| 8-K · Current report | Nov 14, 2025 | Results | SEC |
| DEFA14A · Additional proxy material | Nov 13, 2025 | Meeting notice | SEC |
| 8-K · Current report | Nov 13, 2025 | Material contract | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Oct 14, 2025 | Big-stake notice | SEC |
| 8-K · Current report | Sep 8, 2025 | Current report | SEC |
| 10-Q · Quarterly report | Aug 12, 2025 | Quarterly report | SEC |
| 8-K · Current report | Aug 12, 2025 | Results | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Jul 9, 2025 | Big-stake notice | SEC |
| 424B5 · Prospectus | Jun 16, 2025 | Offer document | SEC |
| 8-K · Current report | Jun 13, 2025 | Meeting outcome | SEC |
| 10-Q/A · Quarterly report, amended | Jun 11, 2025 | Quarterly report | SEC |
| 10-K/A · Annual report, amended | Jun 11, 2025 | Annual report | SEC |
| DEFR14A | Jun 11, 2025 | Meeting notice | SEC |
| SCHEDULE 13G · Big-stake notice | May 30, 2025 | Big-stake notice | SEC |
| 4 · Change in ownership | May 23, 2025 | Insider trade | SEC |
| 4 · Change in ownership | May 23, 2025 | Insider trade | SEC |
| 4 · Change in ownership | May 23, 2025 | Insider trade | SEC |
| 4 · Change in ownership | May 23, 2025 | Insider trade | SEC |
| 4 · Change in ownership | May 23, 2025 | Insider trade | SEC |
| 4 · Change in ownership | May 23, 2025 | Insider trade | SEC |
| 4 · Change in ownership | May 23, 2025 | Insider trade | SEC |
| 4 · Change in ownership | May 23, 2025 | Insider trade | SEC |
| 4 · Change in ownership | May 23, 2025 | Insider trade | SEC |
| 4 · Change in ownership | May 21, 2025 | Insider trade | SEC |
| 8-K · Current report | May 20, 2025 | Current report | SEC |
| 4 · Change in ownership | May 16, 2025 | Insider trade | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | May 15, 2025 | Big-stake notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | May 15, 2025 | Big-stake notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | May 15, 2025 | Big-stake notice | SEC |
| S-8 · Registration statement for employee plans | May 14, 2025 | Offer document | SEC |
| 10-Q · Quarterly report | May 14, 2025 | Quarterly report | SEC |
| 8-K · Current report | May 14, 2025 | Results | SEC |
| 4 · Change in ownership | May 1, 2025 | Insider trade | SEC |
| 3 · Initial statement of ownership | May 1, 2025 | Insider trade | SEC |
| ARS · Annual report to shareholders | Apr 29, 2025 | Annual report | SEC |
| DEF 14A · Proxy statement | Apr 29, 2025 | Meeting notice | SEC |
| 8-K · Current report | Apr 25, 2025 | Current report | SEC |
| 8-K · Current report | Apr 21, 2025 | Management or board change | SEC |
| 8-K · Current report | Apr 8, 2025 | Management or board change | SEC |
| 8-K · Current report | Mar 27, 2025 | Management or board change | SEC |
| 10-K · Annual report | Mar 24, 2025 | Annual report | SEC |
| 8-K · Current report | Mar 24, 2025 | Results | SEC |
| SCHEDULE 13G · Big-stake notice | Mar 10, 2025 | Big-stake notice | SEC |
| 8-K · Current report | Mar 10, 2025 | Current report | SEC |
| SCHEDULE 13D/A · Big-stake notice, amended | Mar 7, 2025 | Big-stake notice | SEC |
| SCHEDULE 13G · Big-stake notice | Mar 3, 2025 | Big-stake notice | SEC |
| UPLOAD · Letter from the SEC | Feb 28, 2025 | Other filings | SEC |
| 8-K · Current report | Feb 24, 2025 | Meeting outcome | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Feb 14, 2025 | Big-stake notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Feb 14, 2025 | Big-stake notice | SEC |
| 8-K · Current report | Feb 7, 2025 | Current report | SEC |
| DEF 14A · Proxy statement | Jan 23, 2025 | Meeting notice | SEC |
| SCHEDULE 13D · Big-stake notice | Jan 22, 2025 | Big-stake notice | SEC |
| SCHEDULE 13G · Big-stake notice | Jan 13, 2025 | Big-stake notice | SEC |
| SCHEDULE 13G · Big-stake notice | Jan 13, 2025 | Big-stake notice | SEC |
| PRE 14A · Preliminary proxy statement | Jan 13, 2025 | Meeting notice | SEC |
| SCHEDULE 13G · Big-stake notice | Jan 8, 2025 | Big-stake notice | SEC |
| 8-K · Current report | Jan 7, 2025 | Material contract | SEC |
| 424B5 · Prospectus | Jan 7, 2025 | Offer document | SEC |
| 8-K · Current report | Jan 6, 2025 | Current report | SEC |
| 424B5 · Prospectus | Jan 6, 2025 | Offer document | SEC |
| 8-K · Current report | Dec 20, 2024 | Current report | SEC |
| SC 13G · Big-stake notice | Nov 14, 2024 | Big-stake notice | SEC |
| 424B3 · Prospectus | Nov 13, 2024 | Offer document | SEC |
| 10-Q · Quarterly report | Nov 13, 2024 | Quarterly report | SEC |
| 8-K · Current report | Nov 13, 2024 | Results | SEC |
| 8-K · Current report | Oct 7, 2024 | Current report | SEC |
| 4/A · Change in ownership, amended | Sep 10, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Sep 4, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Sep 4, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Sep 4, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Sep 4, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Sep 4, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Sep 4, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Sep 4, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Sep 4, 2024 | Insider trade | SEC |
| EFFECT · Notice that a registration is effective | Aug 22, 2024 | Other filings | SEC |
| 424B5 · Prospectus | Aug 21, 2024 | Offer document | SEC |
| CORRESP · Letter to the SEC | Aug 20, 2024 | Other filings | SEC |
| UPLOAD · Letter from the SEC | Aug 19, 2024 | Other filings | SEC |
| S-3 · Registration statement | Aug 14, 2024 | Offer document | SEC |
| 424B3 · Prospectus | Aug 12, 2024 | Offer document | SEC |
| 10-K/A · Annual report, amended | Aug 12, 2024 | Annual report | SEC |
| 8-K · Current report | Aug 12, 2024 | Results | SEC |
| 10-Q · Quarterly report | Aug 12, 2024 | Quarterly report | SEC |
| 8-K · Current report | Aug 6, 2024 | Current report | SEC |
| EFFECT · Notice that a registration is effective | Aug 6, 2024 | Other filings | SEC |
| 424B3 · Prospectus | Aug 5, 2024 | Offer document | SEC |
| CORRESP · Letter to the SEC | Aug 2, 2024 | Other filings | SEC |
| 144 · Notice of proposed sale | Jul 29, 2024 | Other filings | SEC |
| CORRESP · Letter to the SEC | Jul 23, 2024 | Other filings | SEC |
| S-1/A · Registration statement, amended | Jul 23, 2024 | Offer document | SEC |
| UPLOAD · Letter from the SEC | Jul 16, 2024 | Other filings | SEC |
| 8-K · Current report | Jul 9, 2024 | Current report | SEC |
| CORRESP · Letter to the SEC | Jul 9, 2024 | Other filings | SEC |
| UPLOAD · Letter from the SEC | Jun 28, 2024 | Other filings | SEC |
| UPLOAD · Letter from the SEC | Jun 27, 2024 | Other filings | SEC |
| 8-K · Current report | Jun 14, 2024 | Meeting outcome | SEC |
| CORRESP · Letter to the SEC | May 31, 2024 | Other filings | SEC |
| S-1/A · Registration statement, amended | May 31, 2024 | Offer document | SEC |
| 3 · Initial statement of ownership | May 24, 2024 | Insider trade | SEC |
| 8-K · Current report | May 16, 2024 | Management or board change | SEC |
| 10-Q · Quarterly report | May 14, 2024 | Quarterly report | SEC |
| 8-K · Current report | May 14, 2024 | Results | SEC |
| ARS/A · Annual report to shareholders, amended | May 14, 2024 | Annual report | SEC |
| DEFA14A · Additional proxy material | May 14, 2024 | Meeting notice | SEC |
| 10-K/A · Annual report, amended | May 14, 2024 | Annual report | SEC |
| 8-K · Current report | May 3, 2024 | Current report | SEC |
| 8-K · Current report | May 3, 2024 | Current report | SEC |
| UPLOAD · Letter from the SEC | Apr 30, 2024 | Other filings | SEC |
| ARS · Annual report to shareholders | Apr 29, 2024 | Annual report | SEC |
| DEF 14A · Proxy statement | Apr 29, 2024 | Meeting notice | SEC |
| 25-NSE | Apr 29, 2024 | Other filings | SEC |
| 3 · Initial statement of ownership | Apr 18, 2024 | Insider trade | SEC |
| PRE 14A · Preliminary proxy statement | Apr 17, 2024 | Meeting notice | SEC |
| 8-K · Current report | Apr 17, 2024 | Material contract | SEC |
| 4/A · Change in ownership, amended | Apr 16, 2024 | Insider trade | SEC |
| 8-K · Current report | Apr 15, 2024 | Current report | SEC |
| 4 · Change in ownership | Apr 12, 2024 | Insider trade | SEC |
| CORRESP · Letter to the SEC | Apr 2, 2024 | Other filings | SEC |
| S-1/A · Registration statement, amended | Apr 2, 2024 | Offer document | SEC |
| S-8 · Registration statement for employee plans | Apr 1, 2024 | Offer document | SEC |
| 8-K · Current report | Mar 29, 2024 | Current report | SEC |
| 10-K · Annual report | Mar 29, 2024 | Annual report | SEC |
| 10-Q/A · Quarterly report, amended | Mar 29, 2024 | Quarterly report | SEC |
| 8-K · Current report | Mar 29, 2024 | Results | SEC |
| 8-K · Current report | Mar 28, 2024 | Material contract | SEC |
| 4 · Change in ownership | Mar 26, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Mar 21, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Mar 21, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Mar 21, 2024 | Insider trade | SEC |
This page holds 200 of 370 filings. Open Filings
Cap table
Built by 6ix from AEON Biopharma, Inc.’s releases · as of Aug 12, 2026
- Common shares
- 59,084,675
- Fully diluted
- 59,084,675
Fully diluted
| Line | Shares |
|---|---|
| Common shares | 59,084,675 |
Warrants and options
| Lot |
|---|
| Warrants · expiry not stated |
Share count over time
| Count | Shares |
|---|---|
| Nov 22, 2026 | 59,084,675 |
People
6ix reads each seat by machine from the page it links to, and can misread one.
| Person | Seat |
|---|---|
| Shelley Thunen Other companies: LENZ Therapeutics, Inc. (Member · Since at least Mar 21, 2024); RxSight, Inc. (See remarks · Jul 29, 2021 – Apr 14, 2025 · Past) | Director · Since at least Jul 21, 2023 |
| James Lightman Other companies: Wright Medical Group N.V (SVP, General Counsel & Sec · Oct 1, 2015 – Nov 11, 2020 · Past) | Director · Feb 8, 2021 – Feb 8, 2021 · Past |
| Robert J. Palmisano Other companies: RxSight, Inc. (Director · Since at least Jun 18, 2026) | Board Member · Since at least Jun 22, 2026 |
| Vikram Malik Other companies: Evolus, Inc. Common Stock (Director · Since at least Feb 7, 2018) | President, Director · Feb 8, 2021 – Feb 8, 2021 · Past |
| Alex Wilson | Chief Legal & Strategy Officer, Secretary · Since at least Jul 21, 2023 |
| Chad Oh | Chief Medical Officer · Since at least Jul 21, 2023 |
| David Meredith | Chief Legal Officer&Secretary · Feb 8, 2021 – Feb 8, 2021 · Past |
| Eric Carter | Board Member · Since at least Jun 22, 2026 |
| Jennifer Sy | Chief Accounting Officer · Since at least Nov 5, 2026 |
| John Bencich | Chief Financial Officer - · Since at least Apr 3, 2026 |
All 16 people
| Person | Seat |
|---|---|
| Jost Fischer | Director · Since at least Mar 19, 2024 |
| Marc Forth | Board Member · Since at least Nov 13, 2024 |
| Paul Lee | Chief Regulatory Officer · Since at least Nov 5, 2026 |
| Rob Bancroft | President and CEO, Director · Since at least Apr 29, 2025 |
| Seongsoo Park | Director · Apr 12, 2024 – Apr 12, 2024 · Past |
| Shawn Park | Board Member · Since at least Nov 5, 2026 |
Log in to ask 6ix AI your own questions about AEON Biopharma, Inc.